To measure the quality and usefulness of patient information leaflets distributed in Canadian
pharmacies, we compared the information contained in 3 leaflets distributed in Canada for …

Aims To assess the volume of cisapride prescribed in New Zealand to children age 0-17
years and establish whether safety announcements on cisapride had an effect on …

Abstract Purpose 'Dear Doctor'letters alert the prescribing community of drug labeling
changes that contain new contraindications, warnings, adverse reactions, and precautions …

Objectives The Food and Drug Administration and pharmaceutical manufacturers use “Dear
doctor” letters to alert physicians about drug safety. To determine how such warnings may …

Informing healthcare providers of changes and updates in information about
pharmaceuticals during the post-marketing period is essential to assuring continued safe …

Despite the widespread prescription of medicines, patients' knowledge about the drugs they
take is limited. Many people feel that not enough is explained by doctors and pharmacists …

ContextCisapride, a gastrointestinal tract promotility agent, can cause life-threatening
cardiac arrhythmias in patients susceptible either because of concurrent use of medications …

Objective To quantify the impact of the first three label changes and 'Dear Doctor'letters as
sole interventions, sent to prescribers and pharmacists, on the prescribing and dispensing of …

Aim: To assess the impact of European regulations concerning patient information leaflets
(PILs) on the safe and effective use of medicines. Design: Telephone survey Subjects and …

Abstract Background According to the European Community Directive 92/27,
pharmaceutical companies are responsible for working out patient information leaflets (PILs) …